nNOS: a neuronal cytosolic variant commonly localized to post-synaptic densities, and generally accepted to be the most involved enzyme in physiological co-transmission iNOS: a cytosolic variant expressed in a range of cells including transmission-relevant astrocytes and microglia, from which it likely plays an indirect co-transmission role eNOS: a primarily endothelial membrane-localized variant that is likely the least relevant for co-transmission NOS synthesizes NO by deiminating L-arginine into L-citrulline, short circuiting the urea cyclewhen it is present
That's what I lose sleep at night over." Public health advocates and agency scientists strongly pushed back, warning that adding these peptides to the list could set a dangerous precedent
Retrieved 3 December 2025
Pipeline drugs, defined as pharmaceuticals for chronic weight management in development that have not yet been approved for clinical use, were included in the narrative review if human trial data were publicly available with sufficient information on the drugs time of development, clinical phase, MOA, dosing information, and reporting on weight loss outcomes
The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, particularly through microdosing protocols, offers a promising therapeutic approach specifically tailored to address the unique metabolic challenges of this life stage
